

## ASX Announcement

26 August 2019

### **Pro-rata accelerated non-renounceable entitlement offer - notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth)**

This notice is given by Integral Diagnostics Limited (ASX: IDX) (**IDX**) under section 708AA(2)(f) of the *Corporations Act 2001* (Cth) (**Act**) as notionally modified by Australian Securities and Investment Commission Corporations (Non-Traditional Rights Issues) Instrument 2016/84 (**ASIC Instrument 2016/84**).

Where applicable, references in this notice to sections of the Act are to those sections as modified by ASIC Instrument 2016/84.

IDX has announced a pro-rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) of 1 fully paid ordinary share in IDX (**New Shares**) for every 5.91 IDX ordinary shares held as at 7.00pm (Sydney time) on Wednesday, 28 August 2019 by IDX shareholders with a registered address in Australia, New Zealand and certain other jurisdictions in which IDX decides to extend the Entitlement Offer.

IDX confirms that:

- 1 The New Shares will be offered without disclosure under Part 6D.2 of the Act.
- 2 This notice is being given under section 708AA(2)(f) of the Act.
- 3 As at the date of this notice, IDX has complied with:
  - (a) the provisions of Chapter 2M of the Act as they apply to IDX (accounting requirements); and
  - (b) section 674 of the Act (continuous disclosure requirements).
- 4 As at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Act that is required to be set out in this notice under section 708AA(7) of the Act.
- 5 The issue of New Shares under the Entitlement Offer is not expected to have a material effect or consequence on the control of IDX.

Kirsty Lally  
Company Secretary

